Natixis Advisors LLC Raises Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Natixis Advisors LLC raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 104.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 44,335 shares of the biopharmaceutical company’s stock after acquiring an additional 22,653 shares during the quarter. Natixis Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $17,630,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $243,000. Geneos Wealth Management Inc. boosted its holdings in Alnylam Pharmaceuticals by 372.3% in the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 175 shares in the last quarter. Flow Traders U.S. LLC acquired a new position in Alnylam Pharmaceuticals in the second quarter valued at approximately $241,000. Daiwa Securities Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after purchasing an additional 35 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its holdings in Alnylam Pharmaceuticals by 70,300.0% in the second quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock valued at $229,000 after purchasing an additional 703 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $303.05 on Friday. The company has a market capitalization of $40.46 billion, a P/E ratio of 82.80 and a beta of 0.29. Alnylam Pharmaceuticals, Inc. has a twelve month low of $283.10 and a twelve month high of $495.55. The business has a 50 day simple moving average of $307.66 and a 200-day simple moving average of $349.36. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.12. The business had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company’s revenue was up 96.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.44) earnings per share. As a group, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.47 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of the stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $330.42, for a total value of $755,340.12. Following the completion of the sale, the insider directly owned 9,443 shares of the company’s stock, valued at $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 7,740 shares of company stock valued at $2,420,214 over the last three months. Corporate insiders own 0.86% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Jefferies Financial Group reaffirmed a “hold” rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. Canaccord Genuity Group upped their price target on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Bank of America reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Finally, Royal Bank Of Canada lowered their price target on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a report on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $463.13.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.